Avelumab (anti- PD-L1) - Names and Identifiers
Avelumab (anti- PD-L1) - Physico-chemical Properties
Storage Condition | Room Temprature |
Avelumab (anti- PD-L1) - Introduction
Avelumab is a monoclonal antibody drug widely used in the biomedical field. The following is a description of the nature, use, formulation and safety information of Avelumab:
Nature:
Avelumab is a synthetic monoclonal antibody with high specificity and affinity. It is a protein expressed and purified from mammalian cells. The molecular structure of Avelumab allows it to bind to specific antigens and generate an immune response.
Use:
Avelumab is widely used in oncology and immunotherapy. It can bind to protein-specific antigens, thereby preventing or promoting certain biological processes. By inhibiting the interaction between antigen and receptor, Avelumab can inhibit tumor growth, regulate immune function, and improve the ability of the immune system to attack tumors.
Preparation Method:
The preparation process of Avelumab mainly includes the following steps: First, through immunological technology, use specific antigens to stimulate the immune system of mice or other mammals to produce antibodies; Then, extract nucleic acids from lymphocytes obtained from immunized animals; Then, fuse the extracted nucleic acids with tumor cells through fusion experiments to form hybridoma cells; Finally, screen and amplify hybridoma cells, specific antibodies were obtained.
Safety Information:
When using Avelumab, it is necessary to follow relevant safety procedures. In the treatment, patients may have some side effects, such as allergic reactions, fever, fatigue and so on. In addition, due to the regulatory effect of Avelumab on the immune system, patients may have immune-related adverse reactions, such as increased risk of infection. Therefore, before using Avelumab, physicians need to thoroughly evaluate the patient's condition and potential risks, and monitor patients for treatment response and safety.
Last Update:2024-04-09 21:04:16